112 results about "Polymyxin" patented technology

The invention belongs to the technical field of gene engineering, and particularly relates to a mutant of polymyxin efflux transporter and application of the mutant. The mutant is a PmxD transporter mutant, the amino acid sequence of the PmxD transporter mutant is shown as SEQ ID NO: 1, and compared with wild type PmxD, the polymyxin transport capacity of the PmxD transporter mutant (T38W) is improved by 450.46%; and the total discharge amount of polymyxin is increased by 85.72%. Meanwhile, the mutant can significantly improve the growth ability of the strain on a plate containing 250 [mu] g / mL of polymyxin B, namely significantly improve the autoresistance of paenibacillus polymyxa to polymyxin.

The invention discloses an application of NSC348884 in preparation of an antibacterial drug, the bacteria of the NSC348884 are gram-negative bacteria or drug-resistant gram-negative bacteria, and the gram-negative bacteria are acinetobacter baumannii, escherichia coli, pseudomonas aeruginosa or klebsiella pneumoniae; based on an antibacterial drug high-throughput screening technology, it is found from 1280 small molecule compounds that the benzimidazole compound NSC348884 has direct bacteriostasis and sterilization effects on gram-negative bacteria and drug-resistant gram-negative bacteria, and no drug resistance is generated after the benzimidazole compound NSC348884 is continuously applied for 14 days. Further research shows that NSC348884 can interfere with lipid synthesis of gram-negative bacterium cell membranes, inhibit formation of biological membranes and induce lipid metabolism disorder, so that bacteriostatic and bactericidal effects are achieved. In addition, the NSC348884 can also enhance the sensitivity of the drug-resistant bacteria to the imipenem and the polymyxin B.

The invention provides a fluorenyl alcohol derivative which can be used as an antibiotic adjuvant with a broad-spectrum synergistic effect. According to the compound, bacteria outer membrane asymmetric protein MlaC and phospholipase A1 PldA are taken as targets, and a series of fluorenyl alcohol derivatives targeting the bacteria outer membrane asymmetric protein MlaC and phospholipase A1 PldA are obtained through screening. The preferable compound WTU-15 can improve the antibacterial activity of antibiotics such as polymyxin, cefepime, tetracycline and the like on negative bacteria such as sensitive and drug-resistant escherichia coli, salmonella, klebsiella pneumoniae, acinetobacter baumannii and the like, and can also improve the in-vivo treatment effect of cefepime on mice infected by the drug-resistant acinetobacter baumannii. And the visceral organs of the mice survived after administration have fewer bacteria, and the mice are better after being healed. Normal physiological and visceral organ functions of the mouse are not affected by single and continuous administration of the WTU-15.

The invention discloses a bacteriophage lyase and application thereof, and particularly relates to a bacteriophage lyase with an amino acid sequence as shown in SEQ INNO.2. The bacteriophage lyase can inhibit the growth of escherichia coli, staphylococcus and salmonella, can be used as an antibacterial substance in splitting gram-negative bacteria and can be used for preparing drugs for resisting gram-negative bacteria. The lyase can be used independently or compounded with other substances, the use concentration of antibiotics can be reduced by combining the lyase with the antibiotics, toxic and side effects (such as renal toxicity of polymyxin) of drugs are reduced, and meanwhile, generation of bacterial drug resistance is delayed. After the lyase and the chitosan are combined for use, remarkable antibacterial activity is generated, the antibacterial effect can be achieved without pre-treatment on bacteria, and the practicability is improved.

The invention relates to dsRNA capable of simultaneously preventing and treating various thrips and application of the dsRNA. Specifically, the invention provides a dsRNA construct, the construct of the dsRNA is a double strand, and the construct of the dsRNA comprises a nucleotide sequence of an insect nymph and / or adult stage regulation related gene or fragment; wherein the insect nymph and / or adult stage regulation related gene is an Actin gene, and the dsRNA is obtained by amplifying a sequence as shown in SEQ ID NO: 9-10. The fusion type dsRNA is designed to target a plurality of conservative thysanoptera actin gene dsRNA, so that the multi-killing effect is achieved, and the prevention and treatment effect of the fusion type dsRNA is equivalent to that of spinetoram which is commonly used in the market at present.

The invention discloses application of a cyclic peptide compound BIM 23042 or a preparation thereof in preparation of medicines for treating bacterial infectious diseases, and belongs to the technical field of medicines. The invention discloses a cyclic peptide compound BIM 23042 as an antibiotic synergist for the first time, and the cyclic peptide compound BIM 23042 is used for treating bacterial infectious diseases. According to the application disclosed by the invention, the cyclopeptide compound BIM 23042 and polymyxin are combined for use, so that the growth of gram-negative bacteria can be effectively and synergistically inhibited. The combined medication scheme shows a remarkable advantage in coping with acinetobacter baumannii. The cyclic peptide compound BIM 23042 disclosed by the invention has an anti-infection capability, and the anti-infection capability is specifically shown as reducing the inflammatory response of macrophage RAW 264.7 induced by LPS (Lipopolysaccharide) and also reducing the apoptosis of the macrophage RAW 264.7 caused by the LPS. The invention provides a new perspective for developing a novel drug-resistant gram-negative bacterium prevention and control strategy, and also provides a new treatment scheme for coping with bacterial infection.

The invention belongs to the technical field of biology, and provides a pseudomonas aeruginosa endotoxin specific binding polypeptide and application thereof. The amino acid sequence of the polypeptide is shown as SEQ ID No. 1, SEQ ID No. 3 or SEQ ID No. 4 in a sequence table. Experiments prove that the polypeptide has excellent affinity with pseudomonas aeruginosa endotoxin, and compared with an existing anti-endotoxin clinical drug polymyxin B, the polypeptide has obviously better pseudomonas aeruginosa endotoxin detoxification capability. On the basis, the invention further provides application of the polypeptide in removal or separation or analysis of the endotoxin of the pseudomonas aeruginosa and application of the polypeptide in preparation of a detoxification medicine for the endotoxin of the pseudomonas aeruginosa. The polypeptide can be widely applied to the biomedical fields of biological separation, biological detection, disease diagnosis and treatment and the like.

This invention provides the application of dehydrouncitonin in the preparation of drugs that reduce polymyxin toxicity, belonging to the field of pharmaceutical technology. This invention uses dehydrouncitonin in combination with polymyxin. The combined use of dehydrouncitonin and polymyxin E increased the viability of HEK293T and RAW264.7 cells to 87.7% and 94.3%, respectively, with highly significant differences compared to the control, indicating that treatment with dehydrouncitonin in combination with polymyxin E can significantly inhibit the cytotoxic effect of polymyxin E. This invention uses a mouse model to demonstrate that treatment with dehydrouncitonin in combination with polymyxin E can significantly reduce the neurotoxicity and nephrotoxicity of polymyxin E alone in mice, specifically manifested in improved neurobehavioral effects and improved histopathological effects on brain and kidney tissues. This invention uses dehydrouncitonin in combination with polymyxin E to significantly inhibit the cytotoxic, neurotoxic, and nephrotoxic effects of polymyxin E.

The present application relates to the technical field of biology, and particularly relates to a mesenchymal stem cell culture medium and a preparation method and application thereof.The mesenchymal stem cell culture medium comprises a basic culture medium, fetal bovine serum, basic fibroblast growth factor, polymyxin B and deionized water.The present application can simultaneously improve the proliferation activity of mesenchymal stem cells and the secretion performance of HGF by simultaneously adding the basic fibroblast growth factor and the polymyxin B in the basic culture medium; more stem cells can be in the active proliferation and division process by limiting the content of the basic fibroblast growth factor in the mesenchymal stem cell culture medium to 5-50 ng / mL; and the secretion performance of HGF can be improved while the cell proliferation activity is maintained by limiting the content of the polymyxin B in the mesenchymal stem cell culture medium to 50-100 mu g / mL.

The invention relates to the technical field of biological medicine, in particular to application of flufenamic acid in preparation of a polymyxin E antibacterial synergist. The invention discloses an application of flufenamic acid in preparation of a polymyxin E antibacterial synergist, the flufenamic acid has no obvious antibacterial effect on salmonella when being independently used, but the flufenamic acid and polymyxin E can enhance the antibacterial activity of the polymyxin E on the salmonella and reduce the use dosage of the polymyxin E when being jointly used in and out of an animal body, so that the antibacterial effect of the polymyxin E on the salmonella can be enhanced. The antibacterial activity of the polymyxin E on salmonella is enhanced, and the drug resistance of the polymyxin E is inhibited. Flurfenamic acid is approved to be used for other purposes as FDA, and when the flurfenamic acid is combined with polymyxin E, the flurfenamic acid has the characteristic of high safety, and meanwhile, the generation of the drug resistance of the polymyxin E drugs can be effectively avoided. The invention provides a basis for mining a new antibacterial prevention and control strategy for the polymyxin E drug-resistant bacteria.

This invention discloses a polymyxin-resistant, extended-spectrum β-lactamase-producing *Escherichia coli* strain EC382-2-2 and its applications. The *E. coli* strain EC382-2-2 of this invention was deposited on October 27, 2022, at the Guangdong Provincial Microbial Culture Collection Center (GDMCC), located at 5th Floor, Building 59, No. 100 Xianlie Middle Road, Guangzhou, Guangdong Province, China, with accession number GDMCC No: 62929. *E. coli* EC382-2-2 simultaneously carries the *eae* virulence gene, the plasmid-mediated polymyxin resistance gene *mcr-1*, the extended-spectrum β-lactamase gene *CTX-M-55*, and other antibiotic resistance genes. *E. coli* EC382-2-2 carries 18 resistance genes and exhibits high-level resistance to multiple antibiotics, making it a promising model strain for screening novel antimicrobial drugs.

This invention provides a compound drug for treating melioidosis, its preparation method, and its application. The drug comprises active components of traditional Chinese medicine, a bioactive preparation, and a pharmaceutically acceptable carrier. The active components of traditional Chinese medicine are primarily extracts of Scutellaria baicalensis, Coptis chinensis, Fagopyrum dibotrys, and Polygonum cuspidatum. The bioactive preparation includes polymyxin B, homoserine lactonease, and recombinant human β-defensin 3. The components work synergistically to construct a comprehensive intervention system covering all pathological stages, including biofilm disruption, sterilization, anti-endotoxin activity, intracellular bacterial clearance, immune regulation, and tissue repair. This system can effectively disrupt bacterial biofilms, kill multidrug-resistant strains, neutralize endotoxins, and eliminate latent intracellular bacteria, addressing the core pain points of existing melioidosis treatments, such as strong drug resistance, significant toxic side effects, and high recurrence rates. The preparation process of this invention is carried out under low-temperature and sterile conditions throughout, which fully preserves the stability of the active ingredients, making it suitable for industrial production. The drug can be prepared in various dosage forms, covering all clinical subtypes of melioidosis, and possesses clinical application value and promising prospects for widespread application.

This invention relates to a polymyxin Bacillus strain ( Paenibacillus polymyxa This invention relates to B01 and its applications, belonging to the field of microbial technology. The *Bacillus polymyxa* B01 strain disclosed in this invention has been deposited at the Guangdong Provincial Microbial Culture Collection Center, with accession number GDMCC NO.66594. This strain was isolated, purified, and screened from soil samples. Experiments show that this strain has excellent pH and high-temperature tolerance, and the antibacterial active substances produced by its fermentation have good antibacterial effects against *Escherichia coli*, *Pseudomonas aeruginosa*, *Pseudomonas putida*, *Staphylococcus aureus*, *Candida albicans*, *Aspergillus brasiliensis*, *Propionibacterium acnes*, and *Malassezia*. Furthermore, the antibacterial active substances exhibit excellent heat resistance, cold resistance, light stability, pH stability, and preservative effects. It is a mild and low-irritant raw material that can be used to prepare daily chemical products and pharmaceuticals, possessing broad application prospects and significant value for transformational research.

The present application provides a polymyxin prodrug compound with the structure shown in formula (I) or a stereoisomer or a pharmaceutically acceptable salt thereof. The polymyxin prodrug compound of the present application can effectively reduce the biological toxicity of polymyxin, selectively activate in bacterial infected tissues, achieve bacterial killing in infected sites, improve the bioavailability of polymyxin, achieve sustainable development and utilization of classic antibiotics, expand the scope of future clinical application of polymyxin, and has a broad clinical application prospect.

The invention provides Kineococcus G2 and application of the Kineococcus G2 in preparation of a pigment with antioxidant activity, the Kineococcus new strain G2 is CCTCC No. M20242602, the strain is spherical, the size is 1.0 * 1.5 mu m, the optimal growth temperature is 30-37 DEG C, the pH value is 7.0-9.0, and the salt concentration is 1.0%-2.0%. The strain G2 is not sensitive to bacitracin, ciprofloxacin and norfloxacin, and is sensitive to novobiocin, polymyxin, gentamicin, piperacillin, ofloxacin, erythromycin, streptomycin, kanamycin, rifampicin, ampicillin, vancomycin, carbenicillin, chloramphenicol, tetracycline, penicillin, cefoperazone, oxacillin, amoxicillin and neomycin. Pigment generated by fermentation of the G2 strain has good antioxidant activity, and when the concentration is 10 micrograms / mL, the scavenging activity on DPPH is 25.00%, the scavenging activity on hydroxyl radicals is 80.58%, and the iron ion reducing capacity is 1.57, which are all higher than those of contrast beta-carotenoid. The application of the new Kineococcus strain G2 can lay a foundation for the research of antioxidant drugs such as medical treatment and health care product development.

A novel 10 peptide capable of inhibiting the growth of bacteria that are resistant to existing polymyxin, a pharmaceutical composition comprising the novel 10 peptide, and an application thereof in the treatment or prevention of bacterial infections.

The application provides a polymyxin B-loaded nano preparation and a preparation method and application thereof, and belongs to the field of biological nanotechnology.The method comprises the following steps: (1) preparing a water-in-oil emulsion: mixing a water solution of polymyxin B and a dichloromethane solution of polylactic acid-glycolic acid copolymer to obtain a water-in-oil emulsion; (2) preparing an ethanol aqueous solution of hyaluronic acid; (3) mixing the water-in-oil emulsion and the ethanol aqueous solution of hyaluronic acid, and stirring to obtain a nano dispersion; (4) vacuum rotary evaporation of the nano dispersion, collection of a colloidal dispersion, and dispersion of the colloidal dispersion in water to obtain a nano particle solution.The nano preparation prepared by the application does not need a chemical crosslinking agent, and thus effectively avoids problems caused by the introduction of chemical crosslinking.The preparation process is simple and easy to control, has good safety, has good biocompatibility, and provides a basis for the approval of clinical trials and industrial development of atomization drug delivery of antibiotics.

This application discloses a fluorescent probe for labeling the outer membrane of Gram-negative bacteria, its preparation method, and its application. The fluorescent probe uses polymyxin (with its hydrophobic tail and two amino acid residue pairs removed) as a targeting group specifically targeting the outer membrane of Gram-negative bacteria. This structure can specifically bind to the lipopolysaccharide structure in the outer membrane, and is then linked to the fluorophore rhodamine, which has switching properties, to design and synthesize a fluorescent dye. This fluorescent probe, possessing fluorescent switching properties, can be applied to super-resolution imaging of the outer membrane of Gram-negative bacteria.

The invention discloses an antibacterial peptide, a pharmaceutical composition and application, and belongs to the field of polypeptide medicines.The antibacterial peptide forms a novel annular conformation by introducing n-leucine and 2-aminobutyric acid to construct a parent nucleus structure. The affinity of the antibacterial peptide to the main component phosphatidylglycerol of a bacterial cell membrane is remarkably improved, is improved by 31 times or more compared with polymyxin B and is improved by 16 times or more compared with D50 peptide, and the selectivity of the antibacterial peptide to the main component phosphatidylcholine of a mammalian cell membrane is improved by hundreds of times or more compared with that of a control peptide. The polymyxin B peptide has extremely low toxicity to HK-2 kidney cells, and the biological safety of the polymyxin B peptide is obviously superior to that of polymyxin B and D50 peptide. The minimum inhibitory concentration of the antibacterial peptide to gram-negative bacteria is as low as 0.03 mu g / mL, is about 33 times higher than that of polymyxin B, and is 17-33 times higher than that of D50 peptide. The treatment effect of the antibacterial peptide is obviously superior to that of polymyxin B and D50 peptide in various infection models, and the antibacterial peptide is expected to be developed into a novel anti-infection drug and is used for preventing and treating various infections.

The application belongs to the field of genetic engineering and medical engineering, and discloses virK Application of gene in regulation of Klebsiella pneumoniae virulence. The application finds that the expression level of the gene is significantly increased in polymyxin-resistant mutant strains through transcriptome analysis, virK Further research shows that the expression of the gene is regulated by the PhoP / PhoQ two-component regulatory system. The application constructs virK Gene deletion mutant strains and complementary strains, and compares the virulence difference of the strains in an animal infection model, finds that virK The virulence of the deletion strain is significantly reduced, and the complementary strain can restore the virulence phenotype, indicating that virK The gene plays an important role in the regulation of Klebsiella pneumoniae virulence. The application first finds that PhoP can regulate virK Gene expression, and affects the virulence phenotype of Klebsiella pneumoniae through the regulation pathway, thereby revealing a new virulence regulation mechanism, and providing a theoretical basis for subsequent targeted intervention.

The invention provides an endotoxin adsorbent and a preparation method thereof. The preparation method comprises the following steps: S1, preparing epoxidized styrene-divinyl benzene resin; s2, dispersing the epoxidized styrene-divinyl benzene resin obtained in the step S1 into an organic solvent, wherein the epoxidized styrene-divinyl benzene resin with carboxyl obtained by reaction still contains an epoxy group; s3, mixing and reacting the epoxidized styrene-divinyl benzene resin with carboxyl obtained in the step S2 with a reaction solution containing an amination reagent to obtain styrene-divinyl benzene resin with both amido and carboxyl; s4, the styrene-divinyl benzene resin with the amido and carboxyl obtained in the step S3 reacts with polymyxin B under the action of a condensing agent, and the endotoxin adsorbent is obtained. The endotoxin adsorbent prepared by the method is excellent in adsorption performance, strong in specificity, high in mechanical strength, good in biocompatibility and not easy to fall off.

This invention relates to the field of microbial technology and discloses a biocontrol strain for controlling peanut stem rot, wherein the biocontrol strain is *Bacillus pilaris* (…). Paenibacillus peoriae This invention also provides a biocontrol agent containing this strain and its preparation method. Genomic analysis revealed that this strain contains gene clusters encoding active substances such as fusarium and polymyxin, exhibiting significant antagonistic activity against peanut stem rot fungus, and broad-spectrum inhibitory activity against various plant pathogenic fungi, including wheat stem base rot fungus and rapeseed sclerotinia. Furthermore, this strain possesses the ability to secrete auxin, produce proteases, and produce cellulases. The prepared inoculum, applied through root irrigation, can construct a preventative biological barrier in the rhizosphere, providing both disease prevention and growth promotion effects. This invention provides a highly efficient germplasm resource for the green control of crop diseases.

The application provides a recombinant polymyxin enzyme and a preparation and application method thereof, an amino acid sequence of the recombinant polymyxin enzyme is shown as SEQ ID NO. 1, and the recombinant polymyxin enzyme is obtained through site-directed mutation on an amino acid sequence of a wild-type polymyxin enzyme derived from Brevibacillus laterosporus. The recombinant polymyxin enzyme can specifically recognize and cut a peptide bond between a tripeptide side chain and a cyclic heptapeptide ring in a polymyxin structure and a peptide bond between threonine and diaminobutyric acid inside the cyclic heptapeptide ring, and further can specifically degrade or neutralize the recombinant polymyxin enzyme of polymyxin.

The present application belongs to the technical field of antibacterial medicine, and particularly relates to a benzene sulfonyl indole structure modified ruthenium polypyridyl complex with the function of inhibiting bacterial toxin as well as a preparation method and application thereof. The benzene sulfonyl indole structure modified ruthenium polypyridyl complex has the following structure: The benzene sulfonyl indole structure modified ruthenium polypyridyl complex not only has excellent antibacterial ability, but also does not induce bacterial drug resistance. The benzene sulfonyl indole structure modified ruthenium polypyridyl complex can be used in combination with polymyxin B to achieve better antibacterial effect. In addition, it is found that the benzene sulfonyl indole structure modified ruthenium polypyridyl complex has certain antibiofilm effect, and the mechanism thereof is further studied. The complex can also effectively inhibit the hemolysis phenomenon caused by bacteria and has concentration dependence.

The application relates to the technical field of biological medicine, and particularly discloses application of indole-3-methanol in preparation of polymyxin antibacterial synergist and a gram-negative bacterium-resistant pharmaceutical composition, the application of the indole-3-methanol in preparation of the polymyxin antibacterial synergist, the concentration of the polymyxin and the indole-3-methanol is 0.01-2 (mu g / mL):0.01-10 mM; the gram-negative bacterium-resistant pharmaceutical composition comprises the polymyxin and the indole-3-methanol, and further comprises pharmaceutically acceptable adjuvants and / or carriers; the composition can be prepared into injections, ointments or aerosols, and can be used for treating klebsiella pneumoniae, bauman acinetobacter, escherichia coli or pseudomonas aeruginosa and the like; the application discloses that the indole-3-methanol can synergize with the polymyxin, significantly improves the bactericidal activity of the polymyxin on gram-negative bacteria, reduces the use dosage of the polymyxin, improves the antibacterial efficacy, prolongs the antibacterial time, and delays the generation of drug resistance.

The application belongs to the technical field of biological medicine, and discloses application of Ebselen as a synergist of polymyxin in inhibition of salmonella. It is found that Ebselen combined with polymyxin has good synergistic effect on salmonella in vitro and in vivo experiments. In a mouse salmonella infection model, the bacterial load in the liver of animals treated with EBS combined with polymyxin is significantly lower than that treated with single drug. The survival rate of animals treated with EBS combined with polymyxin is significantly higher than that treated with EBS and polymyxin alone. Compared with traditional antibiotics and antibiotic combination to kill salmonella, the synergistic bactericidal effect of Ebselen and polymyxin is less likely to induce bacterial drug resistance, and Ebselen has the characteristics of wide source, multiple effects and good treatment effect, which has good research and application significance for exploring antibiotic synergistic replacement and solving bacterial drug resistance.

The invention discloses an application of combination of anwuligan and polymyxin in synergistic antibiosis. In particular discloses an antibacterial composition which comprises anwuligan and polymyxin, and further discloses application of the antibacterial composition in preparation of a medicine for treating gram-negative bacterium infection and application of the antibacterial composition in preparation of a medicine for reducing the clinical use dosage of the polymyxin. The invention further discloses a method for inhibiting gram-negative bacteria in vitro and a method for enhancing the antibacterial effect of polymyxin. The MIC (minimal inhibitory concentration) of the polymyxin on the escherichia coli ATCC25922 can be reduced by 64 times (FICIlt; 0.5), and the MIC (minimal inhibitory concentration) of mcr-1 polymyxin-resistant escherichia coli (D24800) is reduced by 4 times. The anwulipin and the polymyxin are combined for use, and a synergistic effect is achieved by destroying the integrity of bacterial cell membranes and interfering oxidation balance. The invention provides a new strategy for overcoming the drug resistance of polymyxin.

The invention discloses an artificial synthesis method and application of malonyl coenzyme A. An artificial synthesis route for synthesizing malonyl-CoA by taking beta-alanine (beta-ala) as a precursor is constructed by heterologous expression of aminotransferase and malonyl-CoA reductase: firstly, under the catalysis of transaminase, amino of beta-ala is transferred to alpha-keto acid (such as pyruvic acid, oxaloacetic acid or alpha-ketoglutaric acid and the like), and then the malonyl-CoA is obtained; an intermediate product 3-oxopropionic acid and corresponding amino acid are formed; and the malonyl-CoA is generated from the 3-oxopropionic acid under the action of the malonyl-CoA reductase. According to the method, the defects existing in a natural malonyl-CoA synthesis route, such as low carbon utilization rate, energy substance ATP consumption, greenhouse gas CO2 release, pyruvate dehydrogenase (PDH) of route enzymes and acetyl-CoA carboxylase (ACC) which are strictly regulated and controlled, are overcome, and high yield of products taking malonyl-CoA as a precursor, including light flavomycin, octanoic acid, phloroglucinol, pentadecheptaene, natamycin, spinosad and the like, is realized.

The invention relates to a multifunctional bacterial cellulose gel film and a preparation method and application thereof.The gel film is synthesized by acetobacter xylinum in situ in a fermentation medium containing polymyxin B and panax notoginseng saponins, the gel film is of a three-dimensional network structure, the polymyxin B and the panax notoginseng saponins are wrapped in a bacterial cellulose network, and the polymyxin B and the panax notoginseng saponins are evenly distributed in the bacterial cellulose network. And the fiber diameter of the gel film is 48.68 + / -5 nm. The prepared wound dressing has the wet adhesion characteristic and can effectively promote rapid and scar-free healing of chronic infectious wounds and large-area wounds, so that the method is expected to be widely applied to green synthesis of the wound dressing with antibacterial and wound healing promoting functions, and a new form is provided for use of the pseudo-ginseng powder and the polymyxin B.

The invention relates to the technical field of microbiological detection, in particular to a method for detecting clostridium in cosmetics. The invention provides a modified reinforced clostridium culture medium, a modified Columbia agar culture medium and a method for detecting clostridium in cosmetics, and the method is specifically as follows: the modified reinforced clostridium culture medium can inhibit the activity of preservatives in the cosmetics and improve the clostridium detection rate by adding Tween 80, lecithin and sodium thiosulfate; according to the modified Columbia agar culture medium, polymyxin B and gentamicin in a specific proportion are added, so that interference of non-target bacteria can be effectively inhibited, and detection specificity is enhanced. Based on the two modified culture media, the detection method established by the invention adopts a sample preparation mode of normal temperature and heating dual-condition treatment, and the detection rate of target bacteria can be remarkably improved. The method has the advantages of rapidness, high efficiency, high specificity, high detection rate, low cost, simplicity and convenience in operation and the like, and is particularly suitable for rapid screening requirements of supervision departments and detection mechanisms.